Butabindide oxalate

CCK-inactivating serine protease inhibitor CAS# 185213-03-0

Butabindide oxalate

Catalog No. BCC7020----Order now to get a substantial discount!

Product Name & Size Price Stock
Butabindide oxalate: 5mg $115 In Stock
Butabindide oxalate: 10mg Please Inquire In Stock
Butabindide oxalate: 20mg Please Inquire Please Inquire
Butabindide oxalate: 50mg Please Inquire Please Inquire
Butabindide oxalate: 100mg Please Inquire Please Inquire
Butabindide oxalate: 200mg Please Inquire Please Inquire
Butabindide oxalate: 500mg Please Inquire Please Inquire
Butabindide oxalate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Butabindide oxalate

Number of papers citing our products

Chemical structure

Butabindide oxalate

3D structure

Chemical Properties of Butabindide oxalate

Cas No. 185213-03-0 SDF Download SDF
PubChem ID 56972132 Appearance Powder
Formula C19H27N3O6 M.Wt 393.44
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in water and to 100 mM in DMSO
Chemical Name (2S)-1-[(2S)-2-aminobutanoyl]-N-butyl-2,3-dihydroindole-2-carboxamide;oxalic acid
SMILES CCCCNC(=O)C1CC2=CC=CC=C2N1C(=O)C(CC)N.C(=O)(C(=O)O)O
Standard InChIKey KKMJFDVOXSGHBF-SLHAJLBXSA-N
Standard InChI InChI=1S/C17H25N3O2.C2H2O4/c1-3-5-10-19-16(21)15-11-12-8-6-7-9-14(12)20(15)17(22)13(18)4-2;3-1(4)2(5)6/h6-9,13,15H,3-5,10-11,18H2,1-2H3,(H,19,21);(H,3,4)(H,5,6)/t13-,15-;/m0./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Butabindide oxalate

DescriptionPotent, reversible, selective and competitive inhibitor of a CCK-inactivating serine protease (tripeptidyl peptidase II) (Ki = 7 nM). Active in vivo (ID50 = 1.1 and 6.8 mg/kg i.v. for inhibition of liver and brain enzyme respectively).

Butabindide oxalate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Butabindide oxalate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Butabindide oxalate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.5417 mL 12.7084 mL 25.4168 mL 50.8337 mL 63.5421 mL
5 mM 0.5083 mL 2.5417 mL 5.0834 mL 10.1667 mL 12.7084 mL
10 mM 0.2542 mL 1.2708 mL 2.5417 mL 5.0834 mL 6.3542 mL
50 mM 0.0508 mL 0.2542 mL 0.5083 mL 1.0167 mL 1.2708 mL
100 mM 0.0254 mL 0.1271 mL 0.2542 mL 0.5083 mL 0.6354 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Butabindide oxalate

Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors.[Pubmed:10691692]

J Med Chem. 2000 Feb 24;43(4):664-74.

The cholecystokinin-8 (CCK-8)-inactivating peptidase is a serine peptidase which has been shown to be a membrane-bound isoform of tripeptidyl peptidase II (EC 3.4.14.10). It cleaves the neurotransmitter CCK-8 sulfate at the Met-Gly bond to give Asp-Tyr(SO(3)H)-Met-OH + Gly-Trp-Met-Asp-Phe-NH(2). In seeking a reversible inhibitor of this peptidase, the enzymatic binding subsites were characterized using a fluorimetric assay based on the hydrolysis of the artificial substrate Ala-Ala-Phe-amidomethylcoumarin. A series of di- and tripeptides having various alkyl or aryl side chains was studied to determine the accessible volume for binding and to probe the potential for hydrophobic interactions. From this initial study the tripeptides Ile-Pro-Ile-OH (K(i) = 1 microM) and Ala-Pro-Ala-OH (K(i) = 3 microM) and dipeptide amide Val-Nvl-NHBu (K(i) = 3 microM) emerged as leads. Comparison of these structures led to the synthesis of Val-Pro-NHBu (K(i) = 0.57 microM) which served for later optimization in the design of butabindide, a potent reversible competitive and selective inhibitor of the CCK-8-inactivating peptidase. The strategy for this work is explicitly described since it illustrates a possible general approach for peptidase inhibitor design.

Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster.[Pubmed:9668104]

J Biol Chem. 1998 Jul 24;273(30):19173-82.

We describe the characterization, cloning, and genetic analysis of tripeptidyl peptidase II (TPP II) from Drosophila melanogaster. Mammalian TPP II removes N-terminal tripeptides, has wide distribution, and has been identified as the cholecystokinin-degrading peptidase in rat brain. Size exclusion and ion exchange chromatography produced a 70-fold purification of dTPP II activity from Drosophila tissue extracts. The substrate specificity and the inhibitor sensitivity of dTPP II is comparable to that of the human enzyme. In particular, dTPP II is sensitive to butabindide, a specific inhibitor of the rat cholecystokinin-inactivating activity. We isolated a 4309-base pair dTPP II cDNA which predicts a 1354-amino acid protein. The deduced human and Drosophila TPP II proteins display 38% overall identity. The catalytic triad, its spacing, and the sequences that surround it are highly conserved; the C-terminal end of dTPP II contains a 100-amino acid insert not found in the mammalian proteins. Recombinant dTPP II displays the predicted activity following expression in HEK cells. TPP II maps to cytological position 49F4-7; animals deficient for this interval show reduced TPP II activity.

Characterization and inhibition of a cholecystokinin-inactivating serine peptidase.[Pubmed:8602240]

Nature. 1996 Apr 4;380(6573):403-9.

A cholecystokinin (CCK)-inactivating peptidase was purified and identified as a membrane-bound isoform of tripeptidyl peptidase II (EC 3.4.14.10), a cytosolic subtilisin-like peptidase of previously unknown functions. The peptidase was found in neurons responding to cholecystokinin, as well as in non-neuronal cells. Butabindide, a potent and specific inhibitor, was designed and shown to protect endogenous cholecystokinin from inactivation and to display pro-satiating effects mediated by the CCKA receptor.

Keywords:

Butabindide oxalate,185213-03-0,Natural Products,Other Proteases, buy Butabindide oxalate , Butabindide oxalate supplier , purchase Butabindide oxalate , Butabindide oxalate cost , Butabindide oxalate manufacturer , order Butabindide oxalate , high purity Butabindide oxalate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: